More than 130 suppliers
ISO certified
In-house tech support
we Connect you
Bio-Connect
ProductsBack/LY-333,531 . hydrochloride [169939-93-9]
Chemical Structure
Chemical Structure
Chemical Structure

LY-333,531 . hydrochloride [169939-93-9]

Research Use Only
AG-CR1-0087
AdipoGen Life Sciences
CAS Number169939-93-9
DownloadMSDS
Product group Chemicals
Estimated Purity>98%
Molecular Weight468.6 . 36.5
Price on request
Packing Size
Large volume orders?
Order with a bulk request
More than 130 suppliers
ISO certified
In-house tech support

Overview

  • Supplier
    AdipoGen Life Sciences
  • Product Name
    LY-333,531 . hydrochloride [169939-93-9]
  • Delivery Days Customer
    10
  • CAS Number
    169939-93-9
  • Certification
    Research Use Only
  • Estimated Purity
    >98%
  • Hazard Information
    Warning
  • Molecular Formula
    C28H28N4O3 . HCl
  • Molecular Weight
    468.6 . 36.5
  • Scientific Description
    Chemical. CAS: 169939-93-9. Formula: C28H28N4O3 . HCl. MW: 468.6 . 36.5. Isozyme selective inhibitor of protein kinase Cbeta (PKCbeta). PKCbetaI and PKCbetaII isozyme inhibitor. Amelioriates diabetic retinopathy, diabetic peripheral neuropathy and diabetic nephropathy. Anti-cancer and anti-angiogenic compound. Suppresses glucose-induced adhesion of human monocytes to endothelial cells. Suppresses ERK1/2 and Akt phosphorylation. - Isozyme selective inhibitor of protein kinase Cbeta (PKCbeta) [1, 6, 10, 11, 13]. PKCbetaI and PKCbetaII isozyme inhibitor [2-3, 6, 10, 11, 13]. Amelioriates diabetic retinopathy, diabetic peripheral neuropathy and diabetic nephropathy [1, 3, 5-7, 9-11]. Anti-cancer and anti-angiogenic compound [4-5, 8]. Suppresses glucose-induced adhesion of human monocytes to endothelial cells [12]. Suppresses ERK1/2 and Akt phosphorylation [14].
  • SMILES
    Cl.CN(C)C[C@@H]1CCN2C=C(C3=C2C=CC=C3)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=C2C=CC=C1
  • Storage Instruction
    -20°C,2°C to 8°C
  • UNSPSC
    12352200

References

  • Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor: H. Ishii, et al.; Science 272, 728 (1996)
  • (S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H)-dione (LY333531) and related analogues: isozyme selective inhibitors of protein kinase: M.R. Jirousek, et al.; J. Med. Chem. 39, 2664 (1996)
  • Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor: L.P. Aiello, et al.; Diabetes 46, 1473 (1997)
  • Enzymatic rationale and preclinical support for a potent protein kinase C beta inhibitor in cancer therapy: B.A. Teicher, et al.; Adv. Enzyme Regul. 39, 313 (1999)
  • Protein kinase C in the treatment of disease: signal transduction pathways, inhibitors, and agents in development: P.G. Goekjian & M.R. Jirousek; Curr. Med. Chem. 6, 877 (1999)
  • A protein kinase C-beta-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats: J. Nakamura, et al.; Diabetes 48, 2090 (1999)
  • Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC beta inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes: D. Koya, et al.; FASEB J. 14, 439 (2000)
  • Protein kinase C inhibitors as novel anticancer drugs: P.G. Goekjian & M.R. Jirousek; Expert Opin. Investig. Drugs 10, 2117 (2001)
  • Effects of the protein kinase C beta inhibitor LY333531 on neural and vascular function in rats with streptozotocin-induced diabetes: M.A. Cotter, et al.; Clin. Sci. 103, 311 (2002)
  • Ruboxistaurin, a protein kinase C beta inhibitor, as an emerging treatment for diabetes microvascular complications: S.V. Joy, et al.; Ann. Pharmacother. 39, 1693 (2005)